Clinical evaluation of primary human papillomavirus (HPV) testing with extended HPV genotyping triage for cervical cancer screening: A pooled analysis of individual patient data from nine population-based cervical cancer screening studies from China

被引:4
|
作者
Dun, Changchang [1 ,2 ]
Yuan, Meiwen [2 ]
Zhao, Xuelian [2 ]
Hu, Shangying [2 ]
Arbyn, Marc [3 ]
Zhao, Fanghui [1 ,2 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Sch Populat Med & Publ Hlth, Dept Populat Med, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Epidemiol,Canc Hosp, Beijing, Peoples R China
[3] Sci Inst Publ Hlth, Belgian Canc Ctr, Unit Canc Epidemiol, Brussels, Belgium
来源
CANCER MEDICINE | 2024年 / 13卷 / 11期
关键词
cervical cancer; HPV genotyping; pooled analysis; screening; triage; INTRAEPITHELIAL NEOPLASIA; RISK; WOMEN; PREVALENCE; INFECTION; METAANALYSIS; PERFORMANCE;
D O I
10.1002/cam4.7316
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To assess the clinical values of extended human papillomavirus (HPV) genotyping in triage of high-risk HPV-positive women, focusing on the trade-off between cervical precancer detections and colposcopy referrals. Methods: A bivariate random-effects model was used to estimate the diagnostic accuracy of primary HPV screening with following triage strategies to detect cervical precancers: (i) partial genotyping for HPV16/18 combined with cytological testing at atypical squamous cells of undetermined significance threshold (used as the comparator), (ii) genotyping for HPV16/18/58/52, (iii) genotyping for HPV16/18/58/52/33, (iv) genotyping for HPV16/18/58/33/31, (v) genotyping for HPV16/18/58/52/33/31, and (vi) genotyping for HPV16/18/58/52/33/31/39/51. Internal risk benchmarks for clinical management were used to evaluate the risk stratification of each triage strategy. Results: A total of 16,982 women (mean age 46.1 years, range 17-69) were included in this analysis. For CIN3+ detection, triage with HPV16/18/58/33/31 genotyping achieved lower positivity (6.85% vs. 7.35%, p = 0.001), while maintaining similar sensitivity (91.35% vs. 96.42%, p = 0.32) and specificity (94.09% vs. 93.67%, p = 0.56) compared with the comparator strategy. Similar patterns were observed for CIN2+ detection. Women with a positive HPV16/18/58/33/31 genotyping test had high enough risk for CIN3+ for colposcopy referral, while the risk for women with a negative test was below the 1-year return decision threshold according to internal benchmarks. Conclusions: Our findings suggested extended HPV genotyping is of potential to be used as a triage technique integrated into HPV-based cervical cancer screening, leading to reduced need for colposcopy referral while maintaining similar disease detection and efficient risk stratification.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China
    Pan, Qin-Jing
    Hu, Shang-ying
    Zhang, Xun
    Ci, Pu-wa
    Zhang, Wen-hua
    Guo, Hui-qin
    Cao, Jian
    Zhao, Fang-hui
    Lytwyn, Alice
    Qiao, You-lin
    CANCER CYTOPATHOLOGY, 2013, 121 (09) : 473 - 482
  • [22] Clinical Performance of Human Papillomavirus Testing and Visual Inspection With Acetic Acid in Primary, Combination, and Sequential Cervical Cancer Screening in China
    Wang, Margaret Z.
    Feng, Rui-mei
    Wang, Shaoming
    Duan, Xian-zhi
    Li, Dong
    Zhang, Xun
    Mu, Rong
    Qiao, Youlin
    Smith, Jennifer S.
    SEXUALLY TRANSMITTED DISEASES, 2019, 46 (08) : 540 - 547
  • [23] Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (The FASE Study)
    Monsonego, Joseph
    Hudgens, Michael G.
    Zerat, Laurent
    Zerat, Jean-Claude
    Syrjanen, Karl
    Smith, Jennifer S.
    GYNECOLOGIC ONCOLOGY, 2012, 125 (01) : 175 - 180
  • [24] Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study
    Cox, J. Thomas
    Castle, Phillip E.
    Behrens, Catherine M.
    Sharma, Abha
    Wright, Thomas C., Jr.
    Cuzick, Jack
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2013, 208 (03) : 184.e1 - 184.e11
  • [25] Performance of human papillomavirus E6/E7 mRNA assay for primary cervical cancer screening and triage: Population-based screening in China
    Zhang, Jing
    Yang, Di
    Cui, Xiaoli
    Liu, Guangcong
    Cui, Zhumei
    Wang, Chunyan
    Piao, Haozhe
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [26] Clinical Performance of Human Papillomavirus (HPV) Testing versus Cytology for Cervical Cancer Screening: Results of a Large Danish Implementation Study
    Thomsen, Louise T.
    Kjaer, Susanne K.
    Munk, Christian
    Frederiksen, Kirsten
    Ornskov, Dorthe
    Waldstrom, Marianne
    CLINICAL EPIDEMIOLOGY, 2020, 12 : 203 - 213
  • [27] Value of multi-quadrants biopsy: Pooled analysis of 11 population-based cervical cancer screening studies
    Zhao, Yuqian
    Zhao, Fanghui
    Hu, Shangying
    Zhang, Xuanning
    Zhang, Wenhua
    Pan, Qinjing
    Gage, Julia C.
    Sankaranarayanan, Rengaswamy
    Qiao, Youlin
    CHINESE JOURNAL OF CANCER RESEARCH, 2020, 32 (03) : 383 - +
  • [28] Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study
    Castle, Philip E.
    Stoler, Mark H.
    Wright, Thomas C., Jr.
    Sharma, Abha
    Wright, Teresa L.
    Behrens, Catherine M.
    LANCET ONCOLOGY, 2011, 12 (09) : 880 - 890
  • [29] Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology
    Thomsen, Louise T.
    Kjaer, Susanne K.
    Munk, Christian
    Ornskov, Dorthe
    Waldstrom, Marianne
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2021, 100 (03) : 394 - 402
  • [30] Evolution and future of cervical cancer screening: from cytology to primary HPV testing and the impact of vaccination
    El-Zein, Mariam
    Franco, Eduardo L.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2025,